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Summary The natural history of transitional cell carcinoma (TCC) of the urinary bladder is somewhat
variable, with a significant number of tumour recurrences that occasionally evolve towards an infiltrating
disease. The aim of this study was to investigate the presence of human papillomavirus (HPV) DNA in 76
TCC specimens, and then correlate such findings with the overall patient survival. However, other classical
prognostic clinical and pathological variables such as pathological grade and stage, koilocytosis, age and sex
were also tested. HPV DNA was investigated by means of the highly sensitive polymerase chain reaction
(PCR). DNA primers specific for HPV types 6, 11, 16 and 18 were used. Our results showed that 7 (9.21%)
out of 76 such cases were reactive for HPV 16 DNA; one of them also reacted with HPV 6 DNA. The
statistical analysis was done by the Kaplan-Meier method, Wilcoxon's generalised test for studying the
differences in survival curves and Cox's regression analysis for independent prognostic factors. A significant
P-value was found for pathological grade (P<0.0001) and stage (P<0.0001), HPV 16 DNA (P = 0.0418) and
koilocytosis (P = 0.0140). Thus, pathological grade was the only independent factor in the bladder cancer
survival. These observations may prove useful in prognostic stratification of patients with TCC of the bladder.
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The presence of human papillomavirus (HPV) DNA has
been reported most frequently in association with cervical
dysplasias which can progress to malignancies, and benign
condylomata acuminata (Stoler et al., 1992; Donalson et al.,
1993). Recent studies indicate that some HPVs are associated
with bladder carcinoma (Del Mistro et al., 1988; Kitamura et
al., 1988; Querci Della Rovere et al., 1988; Bryant et al.,
1991; Anwar et al., 1992; Chetsanga et al., 1992; Lopez-
Beltran et al., 1992a; Furihata et al., 1993; Chang et al.,
1994; Lopez-Beltran and Munioz, 1995). However, the exact
incidence of HPV DNA involved in TCC of the bladder
remains controversial (Chang et al., 1994; Lopez-Beltran and
Muiioz, 1995), since the reported incidence varies between
2.5% and 62% (Anwar et al., 1992; Chetsanga et al., 1992;
Lopez-Beltran et al., 1992a; Lopez-Beltran and Mufioz 1995).
Negative results have been reported by Chang et al. (1994)
and Ashfaq and Vuitch (1994). The prognostic implication of
HPV infection in bladder cancer survival was suggested by
Lopez-Beltran et al. (1992a) and Furihata et al. (1993), using
non-isotopic DNA in situ hybridisation.
The aim of the present research was to investigate HPV
incidence in 76 TCC specimens, using polymerase chain reac-
tion (PCR) analysis, and then to correlate such findings with
the overall patient survival. This study also included other
classic prognosticators, such as the pathological grade and
stage, patient age and sex, and koilocytosis. An attempt is
also made to ascertain their possible prognostic implication
in bladder cancer survival.
Materials and methods
The study group consisted of 76 unselected and consecutive
cases of TCC of the urinary bladder received at Reina Sofia
University Hospital (Cordoba, Spain). All 76 patients under-
went transurethral resection (TUR). Their mean age was
66.57 ± 1.17. Fourteen patients were female. Selected tissue
specimens from all biopsies, formalin-fixed paraffin-em-
bedded, were analysed for pathological grade and stage. All
cases were followed over 5 years. Koilocytosis in TCC was
evaluated following the criteria proposed by Hartveit et al.
(1992).
Sample preparationfor PCR
The paraffin-embedded tissues for PCR analysis were cut into
5- 10m thin sections. To prevent contamination from one
paraffin block to another, the knife and the microtome speci-
men holder were carefully cleaned with xylene after each
specimen had been processed. To extract DNA, each section
was placed into Eppendorf tubes and the paraffin removed
twice with xylene and washed once with 0.5 ml of 100%
ethanol to remove the solvent. The samples were then dried
and resuspended in 300 eLI of digestion buffer (50 mM Tris pH
8.5; 1 mM EDTA; 0.5% Tween 20 and 200 1gml-' of pro-
teinase K), and incubated for 6 h at 55°C. After this incuba-
tion the samples were heated at 95°C for 8 min to inactivate
the proteinase K. DNA was then extracted twice with
phenol-chloroform and the aqueous phase precipitated with
95% ethanol at - 20°C overnight. After centrifugation at
13 000 r.p.m. for 15 min the DNA pellet was dried and dis-
solved in 50 j1l of distilled water. The DNA was stored at
- 20°C until use.
PCR analysis
PCR was performed mixing 10 il of DNA with 90 il of a
solution containing 2 mM magnesium chloride, 50 mM
potassium chloride, 1OmM Tris-HCl, pH 8.3, 0.01% gelatin,
200 ILM dNTP, 2.5 U of Taq DNA polymerase and 2 JSM of
the following primers: for HPV type 6, the primers were
HPV601 and HPV602, which amplify a region of 260 bp in
the E5 gene. For HPV type lI the primers were HPV1 14 and
HPV1 15, which amplify a region of 350 bp in the LI gene.
For HPV type 16 and HPV type 18, the upstream primer was
HI which is common for both virus strains, and the down-
stream primers were H2 and H3 respectively, which amplify a
109 bp region from the open reading frame of the E6 gene
(Table I). The primers were synthesised using an Applied
Biosystem 381A DNA synthesiser (Foster City, CA, USA).
The reaction was performed in an automated thermocycler
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Table I Sequence of synthetic oligonucleotide primers and complementary oligonucleotide probes used for the PCR in this
study
Length (bp) of
HPV type/gene Primer or probe Sequence (5' to 3') amplified products
HPV 6/E5 Primer HPV-601 TAGTGGGCCTATGGCTCGTC 260
Primer HPV-602 TCCATTAGCCTCCACGGGTG
Probe HPV-603 CATTAACGCAGGGGCGCCTGAAATTGTGCC
HPV Il/LI Primer HPV-114 GGAATACATGCGCCATGTGG 350
Primer HPV-115 CGAGCAGACGTCCGTCCTCG
Probe HPV-1 16 CGCCTCCACCAAATGGTACACTGGAGG
HPV 16/E6 Primer HI ATTAGTGAGTATAGACATTA 109
Primer H2 GGCTTTTGACAGTTAATACA
Probe H4 ATGGAACAACATTAGAACAGCAATACAACAAACCGTTGTG
HPV 18/E6 Primer HI ATTAGTGAGTATAGACATTA 109
Primer H3 GGTTTFCTGGCACCGCAGGCA
Primer H5 ATGGAGACACATTGGAAAAACTAACTAACACTGGGTTATA
Table II Selected variables representative of the 76 cases of TCC included in this study
No. deceased No. alive Overall no.
Factors Categories (%) (%) P-value (%)
No. of patients 22 (100.0) 54 (100.0) 76 (100.0)
Agea Mean±s.d. 66.84±2.45 66.88± 1.34 66.57± 1.17
Sex Male 18 (81.8) 44 (81.4) 62 (81.6)
Female 4 (18.1) 10 (18.5) 14 (18.4)
P=0.8616
Grade I - (0.0) 14 (25.9) 14 (18.4)
II 4 (18.1) 24 (44.4) 28 (36.8)
III 18 (81.8) 16 (29.6) 34 (44.7)
P=0.0001bC
Stage 0 - (0.0) 8 (14.8) 8 (10.5)
A 7 (31.8) 38 (70.3) 45 (59.2)
B 11 (50.0) 8 (14.8) 19 (25.0)
C 4 (18.1) - (0.0) 4 (5.2)
P= O.OOO1b
HPV 16 + 5 (22.7) 2 (3.7) 7 (9.2)
17 (77.2) 52 (96.2) 69 (90.7)
p=0.0418b
Koilocytosis + 4 12 16 (21.0)
18 42 60 (79.0)
P= 0.0140b
'Age at diagnosis (years). bSignificant P-value. clndependent prognostic factor using Cox regression
analysis.
(Perkin-Elmer, CT, USA) programmed for 40 cycles of DNA
denaturation (95°C), primer annealing (65°C) and template
extension (72°C). In the last cycle the extension step was
7 min. Amplified DNA fragments were hybridised with
specific [32P]ATP end-labelled probes. The complexes were
electrophoresed in 12% SDS/PAGE gels, which were dried
and exposed to XAR film for different periods of time.
Primers PCO3 and PCO4 which amplified a 110 bp fragment
of the human P-globin gene, were included as controls for the
amount of DNA analysed. Necessary precautions to avoid
cross-contamination were taken at all stages of extraction
and amplification (Kwok and Higuchi, 1989).
Statistical analysis
The statistical analysis was undertaken using the life test
procedure. Univariate analysis of cancer-corrected 5 year
survival (defined as death from or with bladder cancer) was
done according to the Kaplan-Meier method (Kaplan and
Meier, 1958). Differences between survival curves were
estimated by the Wilcoxon test (Gehan, 1962). In addition,
independent prognostic factors were sought by Cox regres-
sion analysis (Cox, 1972). A P-value below 0.05 was regarded
as being statistically significant.
Results
The selected variables representative of the 76 TCCs included
in this study are illustrated in Table II. The PCR analysis
showed positive signals for the HPV type 16 DNA in 7
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Figure 1 Autoradiographs of positive signals for HPV DNA
type 16 and HPV DNA type 6, using PCR analysis.
(9.21%) out of 76 cases investigated. Likewise, one case
showed reactivity for both HPV 16 DNA and HPV 6 DNA
(Figure 1). Sixteen (21.0%) out of 76 cases had koilocytosis,
and one of these HPV 16 DNA. Most patients with TCC
(71.4%) associated with HPV DNA were of high patho-
logical grade/stage, and died ofdisease within 9 to 13 months
(Table III).
The univariate chi-squares for the Wilcoxon test showed
pathological grade and stage, the presence of HPV 16-DNA
and koilocytosis, to be significantly related with survival in
all 76 cases. However, pathological grade was found to be an
independent prognostic factor in patient survival (Cox regres-
sion analysis).
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Table III Clinicopathological characteristics of the seven cases of TCC associated with HPV
DNA
Follow-up
Case no. Age Sex (months) Grade Stage PCR 16 Koilocytosis
14 64 M D/13 III B +
16 64 M D/10 III B +a
17 85 M D/10 III A +
22 60 M D/9 III B +
24 57 F NED/60 I 0 + +
28 57 F D/13 III B +
30 51 M NED/60 I A +
aReactive for both HPV DNA type 16 and HPV DNA type 6. D, death; NED, no evidence of
disease; M, male; F, female.
Table IV Studies on HPV DNA of several types investigated in human urinary bladder carcinoma
Reference
Kitamura et al. (1988)
Querci et al. (1988)
Bryant et al. (1991)
Lopez-Beltran et al. (1992a)
Chetsanga et al. (1992)
Anwar et al. (1992)
Wilczynski et al. (1993)
Furihata et al. (1993)
Yu et al. (1993)
Salztein et al. (1993)
Chang et al. (1994)
Ashfaq et al. (1994)
Lopez-Beltran et al. (1995)
Current study
Method/HPV type
DNA studied
SBH/HPV 16
SBH/HPV 11
ISH/HPV 6/11, HPV 16/18
ISH/HPV 6/11,
HPV 16/18, HPV 31/33/35
PCR/HPV 6, 11, 16, 18,
31, 33
ISH/HPV 16
PRC/HPV 6, 11, 16, 18, 33
SBH/PCR/HPV 6, 16, 18
ISH/HPV 16,18,
PCR/HPV
PCR
ISH/PCR/HPV 6, 11, 18,
31, 33, 35, 39, 40, 45, 51-59
ISH 6/11, 16/18, 31/33
ISH/HPV 6/11, 16/18, 31/
33/33
PCR/HPV 6, 11, 16,18
PCR/HPV 6, 11, 16,18
Prevalence HPV type DNA
no. (%) detected
-1/10 (10.0)
al/i (100.0)
12/76 (15.7)
9/18 (50.0)
1/44 (2.5)
10/20(50.0)
39/48 (81.0)
bl/22 (4.5)
28/90 (31.1)
28/53 (52.8)
2/53 (3.7)
0/33 (0.0)
0/108 (0.0)
0/8 (0.0)C
4/76 (5.29)
HPV 16
HPV 11
HPV 16/18
HPV 16/18
HPV 16
HPV16
HPV 16, 18, 33
HPV 6
HPV 16, 18, 33
HPV 16
HPV 18
HPV 6, 11, 16, 18, 31, 33
HPV 16/18
7/76 (9.2) HPV 6, 16
7/76 (9.2) HPV 16/6
a Patient with mild immunodeficiency. b Squamous cell carcinoma. c Two of eight reported cases were
squamous cell carcinoma. SBH, Southern blot hybridisation; ISH, non-isotopic DNA in situ hybridisation.
Discussion
Transitional cell carcinoma of the bladder is a heterogeneous
group of neoplasms that typically present a variable
biological potential including high risk of recurrence and
frequent evolution towards an infiltrating disease with
reduced survival rates (Lopez-Beltran et al., 1994). The prog-
nosis of bladder cancer seems to be related to pathological
factors such as tumour grade and stage, although the
immunohistochemistry of cell and tumour markers as well as
flow cytometric analysis of abnormalities in DNA content
have also been considered prognostically significant (Lopez-
Beltran et al., 1992b). The purpose of this paper was to
determine whether or not the finding of HPV DNA in TCC
has additional prognostic value in patient survival.
HPVs are known to infect man and although most of these
proliferations are benign, some may become malignant, and
this malignant transformation is related to HPV type
(Howley, 1991). In the genitourinary tract, HPV types 6/11
are most commonly associated with genital condylomata
acuminata (Del Mistro, 1988), whereas types 16 and 18 are
associated with dysplasias and carcinomas (Chang, 1990). In
TCC most HPVs were reported in a small number ofpatients
with an immunodeficient status, (Kitamura, 1988; Querci
Della Rovere, 1988). Although, recently a larger series of
TCCs were screened, demonstrating a variable incidence of
HPV DNA which ranged from 2.5% to 62% (Anwar et al.,
1992; Chetsanga et al., 1992; Lopez-Beltran et al., 1992a;
Furihata et al., 1993; Lopez-Beltran and Mufioz, 1995).
Negative results were reported by Chang et al. (1994) and
Ashaq and Vuitch (1994) (Table IV). In addition, HPV 16/18
DNA detected by means of non-isotopic in situ hybridisation
has been related with a poor survival (Lopez-Beltran et al.,
1992a; Furihata et al., 1993). Our results found a 9.2%
incidence of HPV 16 DNA in TCC. Such differences could be
explained by methodological reasons (Ashfaq and Vuitch,
1994). In fact, type and time of fixation have been considered
important parameters for preservation of DNA (Greer et al.,
1991; Karlsen et al., 1994). However, the finding presented
here of a significant relationship between the detection of
HPV 16 DNA and reduced patient survival, using PCR
analysis confirmed previous reports on poor survival of TCC
cases presenting with high-risk HPV DNA (Lopez-Beltran et
al., 1992a; Furihata et al., 1993) detected by using in situ
hybridisation. Taken together these results could indicate an
additional prognostic value of viral infection in bladder
cancer, although pathological grade is the only independent
parameter in the survival of bladder cancer as showed by our
results. This is in agreement with the finding that most
patients with TCC (71.4%) associated with HPV 16 DNA
were of high grade. Such results are of interest since
pathological grade remains an important prognostic para-
meter in survival of patients with TCC of the urinary blad-
der. Finally, we found koilocytosis to be significant in patient
survival, which could be related to the increasing incidence of
koilocytosis concomitant with increasing pathological grade.
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